NICE backs Forxiga for chronic heart failure
Today’s announcement that the UK’s National Institute for Health and Care Excellence (NICE) has published Final Draft Guidance (FDG) recommending dapagliflozin for adult patients with symptomatic chronic heart failure (HF) with preserved or mildly reduced ejection fraction (LVEF of more than 40%) in England and Wales is a significant day for patients and the wider cardiology community.
Dapagliflozin, marketed by UK pharma major AstraZeneca (LSE: AZN) under the trade names Forxiga and Farxiga, is the first and only NICE recommended treatment for this type of heart failure, potentially impacting up to half a million patients in England and Wales.
The drug generated global sales of $4.4 billion for AstraZeneca last year. It is expected to see an increase in uptake with the approval of additional indications, granting AstraZeneca a majority share of the total HF market, according to GlobalData analysts.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze